ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0205

An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study

Ediz Dalkilic1, Dilek Solmaz2, Orhan Kucuksahin3, Erhan Capkin4, Mehmet Emin Derin5, Didem Arslan6, Fatih Noyan7, Nihan Belkis Coskun1, Sadiye Murat8, Omer Faruk Sendur9, Meltem Alkan Melikoglu10, Savas Gursoy11, Taciser Kaya12, Ali Sahin13, Murat Karkucak4, Timur Pirildar14, Mustafa Ender Terzioglu15, Cemal Bes16 and Servet Akar2, 1Uludag University, School of Medicine – Bursa, Turkey, Bursa, Turkey, 2Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, 3Ankara State Hospital, School of Medicine, Ankara, Turkey, 4Karadeniz Technical University, School of Medicine, Trabzon, Turkey, 5Sivas Numune Hospital, Sivas, Turkey, 6Cukurova University, School of Medicine – Adana, Turkey, Adana, Turkey, 7Nazilli State Hospital – Aydın, Turkey, Aydin, Turkey, 8Istanbul Medeniyet University, Goztepe Training and Research Hospital, İstanbul, Turkey, 9Adnan Menderes University, School of Medicine, Aydin, Turkey, 10Ataturk University, School of Medicine, Erzurum, Turkey, 11Gaziantep University, School of Medicine – Gaziantep, Turkey, Gaziantep, Turkey, 12Saglik Bilimleri University, Izmır Bozyaka Trainig and Research Hospital – Izmir, Turkey, Izmir, Turkey, 13Sivas Cumhuriyet University, School of Medicine, Sivas, Turkey, 14Celal Bayar University, School of Medicine – Manisa, Turkey, Manisa, Turkey, 15Akdeniz University, School of Medicine, Antalya, Turkey, 16Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey

Meeting: ACR Convergence 2021

Keywords: , , , ,

Session Information

Date: Saturday, November 6, 2021

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I (0183–0209)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Available evidence suggests that timely and effective management of patients with psoriatic arthritis (PsA) can improve long-term outcomes. Current information on the factors which influence the management decisions for PsA is limited in Turkey. The purpose of this study was to evaluate the impact of clinical rheumatology setting on management steps of patients with a confirmed PsA diagnosis from inflammatory musculoskeletal symptom onset to PsA diagnosis.

Methods: All patients were assessed by both rheumatologists and dermatologists across 30 centers in Turkey, and patients with confirmed diagnosis of PsA according to CASPAR criteria were included in the study. Primary outcome of this study was the timeframe from symptom onset to PsA diagnosis; secondary outcomes were time taken from PsA diagnosis to first conventional synthetic disease-modifying antirheumatic drug (csDMARD) and to first biologic DMARD (bDMARD) including switch data for csDMARD and bDMARD.

Results: Of 287 patients enrolled in the study, 243 patients with confirmed diagnosis of PsA were included in this analysis. It was observed that majority of patients were women (n=147, 60.5%). Of 134 patients in rheumatology setting, mean clinical disease activity PsA score (cDAPSA) was 13.42±14.11, demographic and clinical characteristics of patients included in the rheumatology setting are presented in Table 1. In the rheumatology setting the mean time from symptom onset to diagnosis of PsA was 11.12 ± 52.68 months. The mean time from PsA diagnosis to first csDMARD and bDMARD was 2.62 ± 43.10 and 54.61 ± 76.52 months, respectively. Mean time from first csDMARD to first bDMARD was 37.34 ± 46.68 months. In the rheumatology setting patients showed a significantly shorter mean time from symptom onset to diagnosis (11.12 vs. 17.69 months, as compared to dermatologists). The proportion of patients receiving any treatment for PsA was greater in the rheumatology setting (99.3% vs. 82.5%). A higher proportion of patients with PsA in rheumatology setting were treated with csDMARDs (86.5% vs. 62.2%). The first csDMARD in this setting was methotrexate (79.1%) and first bDMARD was a TNF inhibitor (42.5%). Disease activity of 243 patients determined by cDAPSA scores showed 54 (22.2%) of the patients had remission, 73 (30.0%) had low disease activity, 47 (19.3%) had moderate disease activity, 26 (10.7%) had high disease activity and 43 (17.7 %) patients had missing data.

Conclusion: Our study conducted in several regions in Turkey results and obtained from patients with a confirmed PsA diagnosis who were diagnosed and treated by rheumatologists were similar with the globally published data. These results support again significant collaboration of rheumatology and dermatology specialists recommended by well-accepted treatment guidelines and approaches.

Table 1: Demographic and clinical characteristics of PsA patients from Rheumatology Setting of the LOOP study

Disclosures: E. Dalkilic, AbbVie, 6, MSD, 6, Roche, 6, Pfizer, 6, UCB, 6, Novartis, 6; D. Solmaz, Roche, 6, Farmanova, 6, Pfizer, 6, Lilly, 6; O. Kucuksahin, None; E. Capkin, AbbVie, 2, 6, Roche, 2, 6, MSD, 2, 6, Pfizer, 6; M. Derin, None; D. Arslan, None; F. Noyan, None; N. Coskun, None; S. Murat, None; O. Sendur, None; M. Melikoglu, AbbVie, 6, Pfizer, 6, MSD, 6, UCB, 6; S. Gursoy, Sanofi, 5, Novartis, 5; T. Kaya, None; A. Sahin, AbbVie, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6; M. Karkucak, AbbVie, 6; T. Pirildar, AbbVie, 6; M. Terzioglu, AbbVie, 2, 5, 6, Pfizer, 2, 5, 6, Novartis, 2, 5, 6, Pharmactive, 2, 5, 6, UCB, 2, 5, 6, Boehringer Ingelheim, 2, 5, 6; C. Bes, AbbVie, 2, 6; S. Akar, AbbVie, 2, 5, 6, Lilly, 2, 5, 6, MSD, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Roche, 2, 5, 6, Janssen, 2, 5, 6, UCB, 2, 5, 6, Amgen, 2, 5, 6, Gilead, 2, 5, 6, Abdi Ibrahim, 2, 5, 6, Ilko, 2, 5, 6.

To cite this abstract in AMA style:

Dalkilic E, Solmaz D, Kucuksahin O, Capkin E, Derin M, Arslan D, Noyan F, Coskun N, Murat S, Sendur O, Melikoglu M, Gursoy S, Kaya T, Sahin A, Karkucak M, Pirildar T, Terzioglu M, Bes C, Akar S. An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/an-observational-study-from-the-perspective-of-rheumatology-in-the-management-of-patients-with-psoriatic-arthritis-in-turkey-loop-study/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-observational-study-from-the-perspective-of-rheumatology-in-the-management-of-patients-with-psoriatic-arthritis-in-turkey-loop-study/